8 research outputs found
Serum selenium levels do not differ in type 2 diabetic subjects with and without coronary artery disease
<p>Abstract</p> <p>Background</p> <p>The aim of the present study was to investigate whether selenium levels differ between type 2 diabetic subjects with and without coronary artery disease (CAD).</p> <p>Methods</p> <p>A total of 200 subjects with type 2 diabetes (100 with CAD and 100 without CAD), consecutively selected from the diabetes outpatient clinic of our hospital were enrolled into the study. A detailed medical history and a physical examination were obtained by all the participants.</p> <p>Results</p> <p>Serum selenium levels did not differ between diabetic subjects with and without CAD (102.40 ± 31.10 vs. 108.86 ± 33.88 microg/L, p = 0.16). In diabetic subjects with CAD multivariate linear regression analysis demonstrated significant independent associations between selenium and sex (beta = 0.21, p = 0.03) and glucose levels (beta = 0.25, p = 0.008). In diabetic subjects without CAD multivariate linear regression analysis demonstrated significant independent associations between selenium and peripheral artery disease (beta = 0.16, p = 0.05) and glucose levels (beta = -0.09, p = 0.05).</p> <p>Conclusion</p> <p>Serum selenium levels did not differ between diabetic subjects with and without CAD. In diabetic subjects with CAD, the only determinants of serum selenium levels were sex and glucose levels. In diabetic subjects without CAD the only determinants of serum selenium levels were peripheral artery disease and glucose levels.</p
Development and validation of a GC/MS method for the determination of buprenorphine and norbuprenorphine in blood
Monitoring methadone milk concentrations of methadone-maintained women in postpartum period for breastfeeding safety
Incidence of fatalities of road traffic accidents associated with alcohol consumption and the use of psychoactive drugs: A 7-year survey (2011-2017)
Driving under the influence of alcohol and/or psychoactive substances
increases the risk of severe, even fatal motor vehicle accidents. The
aim of this descriptive study was to present the impact of alcohol
and/or psychoactive substances on fatal road traffic accidents (RTAs)
during the period 2011-2017. For this purpose, the toxicological
investigation reports from the Department of Forensic Medicine and
Toxicology of the University of Athens were used. In total, 1,841
(32.2%) of the autopsies conducted by the Department of Forensic
Medicine and Toxicology of the National and Kapodistrian University of
Athens over a 7-year period (2011-2017) were victims of fatal RTAs.
Blood and urine samples were collected and analyzed for the presence of
alcohol and psychoactive substances. The results were classified
according to sex, age, victim (car driver, motorcyclist, pedestrian, or
passenger) and the date the accident occurred (day, month and year). In
total, 40.7% of the RTA-related fatalities were associated with alcohol
consumption, among which 20.3% were car drivers. Of these, 87.3% were
male victims. A higher frequency of RTA-related fatalities associated
with a blood alcohol concentration (BAC) >110 mg/dl was encountered in
younger compared with older age groups. Psychoactive substances were
detected in 348 (18.9%) of the victims (cannabis in 46.6% of these,
benzodiazepines in 25.9%, opiates in 16.4% and cocaine in 11.1% of
these). The percentage of the RTA-related victims that had consumed
alcohol in combination with other psychoactive substances was 4.5%. On
the whole, the findings of this study suggest that alcohol and
psychoactive substances are probably risk factors for RTA-related
fatalities
Bioanalytical LC–MS Method for the Quantification of Plasma Androgens and Androgen Glucuronides in Breast Cancer
The physiological and pathological development of the breast is strongly affected by the hormonal milieu consisting of steroid hormones. Mass spectrometry (MS) technologies of high sensitivity and specificity enable the quantification of androgens and consequently the characterization of the hormonal status. The aim of this study is the assessment of plasma androgens and androgen glucuronides, in the par excellence hormone-sensitive tissue of the breast, through the application of liquid chromatography–mass spectrometry (LC–MS). A simple and efficient fit-for-purpose method for the simultaneous identification and quantification of dehydroepiandrosterone sulfate (DHEAS), androstenedione (A4), androsterone glucuronide (ADTG) and androstane-3α, 17β-diol-17-glucuronide (3α-diol-17G) in human plasma was developed and validated. The presented method permits omission of derivatization, requires a single solid-phase extraction procedure and the chromatographic separation can be achieved on a single C18 analytical column, for all four analytes. The validated method was successfully applied for the analysis of 191 human plasma samples from postmenopausal women with benign breast disease (BBD), lobular neoplasia (LN), ductal carcinoma in situ and invasive ductal carcinoma (IDC). DHEAS plasma levels exhibited significant differences between LN, IDC and BBD patients (P < 0.05). Additionally, ADTG levels were significantly higher in patients with LN compared with those with BBD (P < 0.05)